Industry think tank urges European approach to regulating AI in drug development

U.S. policymakers should adopt the European Union’s tack of considering the application of artificial intelligence for drug discovery a low-risk use case, according to a report from the Information Technology Innovation Foundation.

The report released Nov. 15 points to a recent paper from the European Medicines Agency in noting “AI applications in drug discovery are typically considered low risk, since drug candidates proposed with AI assistance would still undergo the usual rigorous clinical trial testing.”

“In clinical trials, regulatory...